V4Vendetta
Member
- Joined
- Jul 22, 2007
- Messages
- 2,703
Burzynski Clinic
http://www.burzynskiclinic.com/
http://www.burzynskimovie.com/
9432 Katy Freeway
Houston, Texas 77055
Phone: 713.335.5697
Fax: 713.935.0649
Departments:
Patient Scheduling & Patient Information (USA): [email protected]
International Patients (outside USA): [email protected]
Human Resources: [email protected]
Media/Public Relations & Business Info: [email protected]
Cancer Information Specialist: 1 (800) 714-7181
International Callers: +1 (713) 335-5697
Full Movie about Burzynski, from Burzynski official YouTube channel here:
http://www.youtube.com/watch?v=rBUGVkmmwbk
http://www.burzynskimovie.com/
Burzynski documentary reveals true agenda of FDA and cancer industry to destroy cancer cures that really work
http://www.naturalnews.com/032998_Burzynski_cancer_cures.html
(NaturalNews) As I've written about many times before, the cancer industry with all of its research, campaigns, and fundraising activities is really nothing more than a giant, corrupt business venture. As crazy as it might sound to some, the point of the cancer industry is not really to cure cancer -- it is to keep raising money for the alleged, and never-ending, "search for the cure." And the hard-hitting documentary Burzynski The Movie - Cancer Is Serious Business exposes all this as director Eric Mercola tracks the 14-year battle of Dr. Stanislaw Burzynski -- the man responsible for creating the all-natural, non-toxic cancer cure featured in the film -- to protect his unique protocol from being stolen by the government and Big Pharma, and to defend his freedom to treat cancer patients with unconventional methods.
----------------------------------------------------------------------------------------------
The War on Cancer: One Doctor May Have Discovered a Cure
http://www.bestofyoutoday.com/health-news/war-cancer-one-doctor-may-have-discovered-cure
The Best of You Today is dedicated to the concept that the best cure for disease is prevention. A healthy diet, active lifestyle, and commitment to mental and physical wellness work wonders in our body’s natural ability to prevent disease. But what happens in the case of genetics? Can disease be prevented or cured when a predisposition exists? Dr. Burzynski, founder of the Burzynski Clinic for Cancer Research and filmmaker, offers incredible insight to the possibility of a cure in even the grimmest prognosis. His results are no less than astounding.
On January 22, 1971, President Richard Nixon stood before Congress and announced the beginning of what was become America's longest war: the war on cancer. When he made the announcement, President Nixon thought we would need only five years to cure cancer.
I was just twenty-eight at the time, ready to being my own personal war against cancer.
Two years previously, when I was working on my PhD thesis at the Medical University in Lublin, Poland, I had isolated peptide fractions from the blood and urine of healthy people. I brought these peptide fractions, which were deficient in cancer patients, to America in the fall of 1970 and began research at Baylor College of Medicine in Houston in October.
Over the next five years, we completed our preclinical studies on peptide fractions and identified some of them as antineoplastons. We quickly learned that these antineoplastons could destroy cancer cells without harming normal cells. In 1976, we started treating advanced cancer patients with the new antineoplastons.
Fast forward to 2011. Despite significant successes, forty years after President Nixon declared war on cancer, we are still waiting for the breakthrough. Some prominent doctors have suggested we'll need another thirty or forty years before we can truly conquer cancer.[1] Others, like Dr. Bernadine Healey, former director of the National Institutes of Health, envision a different future: "Imagine cancer in 2040. A 45-year-old woman who has never smoked develops lung cancer.… She undergoes outpatient surgery, and her doctors quickly scrutinize the tumor's genes and feed the data … into a desktop computer that crunches out a treatment plan all but certain to work.”[2]
I have a different view. I don't believe we should have to wait until 2040. Perhaps the cure for cancer is already available, and all we have to do is dramatically change the way we diagnose and treat cancer.
Cancer: A Genetic Disease
Traditional oncology is based on an old and fairly simple model.
In 1845, the prominent German physician Rudolf Virchow introduced the principle of diagnosing cancer with an optic microscope. The methods have become very sophisticated since then, but the principle is the same: look at microscopic slides containing biopsy samples, identify the cancer as one of less than 200 varieties, and treat every patient with the same diagnosis the same way. Treatment is based on surgery and combination chemotherapy drugs with or without radiation therapy. There is no effort to individualize therapy based on the patient's exact cancer.
This is still where we are today. This approach does produce long-term improvement in a few patients, but many more suffer adverse reactions and die. Even success stories include significant trauma for the patient, who frequently must take multiple courses of highly toxic therapies.
A group of medical pioneers felt this was wrong. Instead of a one-size-fits-all approach, they believe that the best approach to cancer goes much deeper, to the genetic level. In this view, cancer should be diagnosed based on genetic abnormalities, and then a therapy can be designed that selectively kills cancer cells by targeting these abnormal genes in the cancer cell. Based on this principle, the cancer diagnosis should be based on the study of cancerous genome in every patient, and cancer therapy should be highly personalized. So far, the FDA has approved 40 drugs that selectively target cancer genes.
Personalized Cancer Treatment
In 1976, I launched clinical trials of antineoplastons in cancer patients. We already knew these unique molecules selectively killed cancer cells without harming normal cells, but there was much to learn.
Surprisingly, as soon as we initiated clinical trials in larger number of patients, the support from the National Cancer Institute and Baylor College of Medicine disappeared.
As a result, I organized my own research laboratory and outpatient clinic. That first laboratory evolved into the modern Burzynski Research Institute, which is a publicly held corporation, and the clinic diversified into a state-of-the-art pharmaceutical plant and the Burzynski Clinic. Since then, we have conducted Phase I and Phase II clinical trials of antineoplastons in advanced cancer without any financial support from the government. In fact, we encountered numerous official roadblocks—these are explained in detail in the documentary Burzynski.
The trials moved forward, however, and we have compiled impressive data on the ability of antineoplastons to treat and cure advanced cancer. So far, eleven prospective Phase II clinical trials that have been registered with the FDA proved the safety and efficacy of antineoplastons in deadly brain tumors. Additionally, randomized, controlled clinical trials conducted with antineoplastons in patients diagnosed with colon cancer that had spread to the liver showed markedly increased survival: 62 percent over five years, compared to only 34 percent in the chemotherapy group.
These kinds of results are possible because of our new understanding of the cancerous process. We now understand cancer as a disease of the genes. In the average cancer cell, a network of 2,400 genes forms to protect and nourish the growing cell.
This understanding is critical to the success we've achieved with antineoplastons. In our laboratory research, we found that antineoplastons are molecular switches that affect approximately 100 genes. They “turn off” oncogenes thatpromote cancer and “turn on” tumor suppressor genes that fight cancer. This makes them superior to the majority of gene-targeted medications that work on a single gene or a small group of genes.
One of the medications from the antineoplastons group, phenylbutyrate, has been approved as a prescription medication, and we began incorporating it into our treatment. Recently, the FDA has given us permission to treat select advanced cancer patients with a combination of intravenous antineoplastons that are currently entering Phase III trials, in combination with other medications. These additional medications are selected based on gene activity throughout the entire genome. We conduct these studies on every patient who comes to our clinic.
Ultimately, our goal is to come up with a treatment plan that covers approximately 200 genes involved in cancer.
So far, we have treated over 1,700 patients diagnosed with a variety of advanced cancers including breast, colon, lung, prostate, and many less common varieties of cancer. Our across-the-board success rate is close to 50 percent objective response. We believe that by using intravenous antineoplastons in combination with targeted medications we can substantially improve our success rate.
During our clinical trials, we accumulated data on 359 incurable brain tumors (gliomas). These are some of the most difficult malignancies to treat; they include glioblastoma and brainstem glioma. After treatment, 88 patients obtained objective responses. A complete response was identified in 57 percent (complete disappearance of the tumors) and partial response was achieved in 43 percent of patients (more than 50 percent reduction of tumor size). Survival in excess of five years was established in 39 percent of patients, and a number of patients have survived tumor free for more than ten years. The truth is that a number of our cancer patients accomplished cure of their disease in some of the most difficult types of malignancies in the entire oncology.
We don’t need to wait another forty years for a cancer cure. A cancer cure exists in America now, but it is available to only a small number of patients, and every patient requires individual permission from the FDA to be treated. The Promised Land is already visible, but it is up to the American people how soon it can be entered.
http://www.burzynskiclinic.com/
http://www.burzynskimovie.com/
9432 Katy Freeway
Houston, Texas 77055
Phone: 713.335.5697
Fax: 713.935.0649
Departments:
Patient Scheduling & Patient Information (USA): [email protected]
International Patients (outside USA): [email protected]
Human Resources: [email protected]
Media/Public Relations & Business Info: [email protected]
Cancer Information Specialist: 1 (800) 714-7181
International Callers: +1 (713) 335-5697
Full Movie about Burzynski, from Burzynski official YouTube channel here:
http://www.youtube.com/watch?v=rBUGVkmmwbk
http://www.burzynskimovie.com/
Burzynski documentary reveals true agenda of FDA and cancer industry to destroy cancer cures that really work
http://www.naturalnews.com/032998_Burzynski_cancer_cures.html
(NaturalNews) As I've written about many times before, the cancer industry with all of its research, campaigns, and fundraising activities is really nothing more than a giant, corrupt business venture. As crazy as it might sound to some, the point of the cancer industry is not really to cure cancer -- it is to keep raising money for the alleged, and never-ending, "search for the cure." And the hard-hitting documentary Burzynski The Movie - Cancer Is Serious Business exposes all this as director Eric Mercola tracks the 14-year battle of Dr. Stanislaw Burzynski -- the man responsible for creating the all-natural, non-toxic cancer cure featured in the film -- to protect his unique protocol from being stolen by the government and Big Pharma, and to defend his freedom to treat cancer patients with unconventional methods.
----------------------------------------------------------------------------------------------
The War on Cancer: One Doctor May Have Discovered a Cure
http://www.bestofyoutoday.com/health-news/war-cancer-one-doctor-may-have-discovered-cure
The Best of You Today is dedicated to the concept that the best cure for disease is prevention. A healthy diet, active lifestyle, and commitment to mental and physical wellness work wonders in our body’s natural ability to prevent disease. But what happens in the case of genetics? Can disease be prevented or cured when a predisposition exists? Dr. Burzynski, founder of the Burzynski Clinic for Cancer Research and filmmaker, offers incredible insight to the possibility of a cure in even the grimmest prognosis. His results are no less than astounding.
On January 22, 1971, President Richard Nixon stood before Congress and announced the beginning of what was become America's longest war: the war on cancer. When he made the announcement, President Nixon thought we would need only five years to cure cancer.
I was just twenty-eight at the time, ready to being my own personal war against cancer.
Two years previously, when I was working on my PhD thesis at the Medical University in Lublin, Poland, I had isolated peptide fractions from the blood and urine of healthy people. I brought these peptide fractions, which were deficient in cancer patients, to America in the fall of 1970 and began research at Baylor College of Medicine in Houston in October.
Over the next five years, we completed our preclinical studies on peptide fractions and identified some of them as antineoplastons. We quickly learned that these antineoplastons could destroy cancer cells without harming normal cells. In 1976, we started treating advanced cancer patients with the new antineoplastons.
Fast forward to 2011. Despite significant successes, forty years after President Nixon declared war on cancer, we are still waiting for the breakthrough. Some prominent doctors have suggested we'll need another thirty or forty years before we can truly conquer cancer.[1] Others, like Dr. Bernadine Healey, former director of the National Institutes of Health, envision a different future: "Imagine cancer in 2040. A 45-year-old woman who has never smoked develops lung cancer.… She undergoes outpatient surgery, and her doctors quickly scrutinize the tumor's genes and feed the data … into a desktop computer that crunches out a treatment plan all but certain to work.”[2]
I have a different view. I don't believe we should have to wait until 2040. Perhaps the cure for cancer is already available, and all we have to do is dramatically change the way we diagnose and treat cancer.
Cancer: A Genetic Disease
Traditional oncology is based on an old and fairly simple model.
In 1845, the prominent German physician Rudolf Virchow introduced the principle of diagnosing cancer with an optic microscope. The methods have become very sophisticated since then, but the principle is the same: look at microscopic slides containing biopsy samples, identify the cancer as one of less than 200 varieties, and treat every patient with the same diagnosis the same way. Treatment is based on surgery and combination chemotherapy drugs with or without radiation therapy. There is no effort to individualize therapy based on the patient's exact cancer.
This is still where we are today. This approach does produce long-term improvement in a few patients, but many more suffer adverse reactions and die. Even success stories include significant trauma for the patient, who frequently must take multiple courses of highly toxic therapies.
A group of medical pioneers felt this was wrong. Instead of a one-size-fits-all approach, they believe that the best approach to cancer goes much deeper, to the genetic level. In this view, cancer should be diagnosed based on genetic abnormalities, and then a therapy can be designed that selectively kills cancer cells by targeting these abnormal genes in the cancer cell. Based on this principle, the cancer diagnosis should be based on the study of cancerous genome in every patient, and cancer therapy should be highly personalized. So far, the FDA has approved 40 drugs that selectively target cancer genes.
Personalized Cancer Treatment
In 1976, I launched clinical trials of antineoplastons in cancer patients. We already knew these unique molecules selectively killed cancer cells without harming normal cells, but there was much to learn.
Surprisingly, as soon as we initiated clinical trials in larger number of patients, the support from the National Cancer Institute and Baylor College of Medicine disappeared.
As a result, I organized my own research laboratory and outpatient clinic. That first laboratory evolved into the modern Burzynski Research Institute, which is a publicly held corporation, and the clinic diversified into a state-of-the-art pharmaceutical plant and the Burzynski Clinic. Since then, we have conducted Phase I and Phase II clinical trials of antineoplastons in advanced cancer without any financial support from the government. In fact, we encountered numerous official roadblocks—these are explained in detail in the documentary Burzynski.
The trials moved forward, however, and we have compiled impressive data on the ability of antineoplastons to treat and cure advanced cancer. So far, eleven prospective Phase II clinical trials that have been registered with the FDA proved the safety and efficacy of antineoplastons in deadly brain tumors. Additionally, randomized, controlled clinical trials conducted with antineoplastons in patients diagnosed with colon cancer that had spread to the liver showed markedly increased survival: 62 percent over five years, compared to only 34 percent in the chemotherapy group.
These kinds of results are possible because of our new understanding of the cancerous process. We now understand cancer as a disease of the genes. In the average cancer cell, a network of 2,400 genes forms to protect and nourish the growing cell.
This understanding is critical to the success we've achieved with antineoplastons. In our laboratory research, we found that antineoplastons are molecular switches that affect approximately 100 genes. They “turn off” oncogenes thatpromote cancer and “turn on” tumor suppressor genes that fight cancer. This makes them superior to the majority of gene-targeted medications that work on a single gene or a small group of genes.
One of the medications from the antineoplastons group, phenylbutyrate, has been approved as a prescription medication, and we began incorporating it into our treatment. Recently, the FDA has given us permission to treat select advanced cancer patients with a combination of intravenous antineoplastons that are currently entering Phase III trials, in combination with other medications. These additional medications are selected based on gene activity throughout the entire genome. We conduct these studies on every patient who comes to our clinic.
Ultimately, our goal is to come up with a treatment plan that covers approximately 200 genes involved in cancer.
So far, we have treated over 1,700 patients diagnosed with a variety of advanced cancers including breast, colon, lung, prostate, and many less common varieties of cancer. Our across-the-board success rate is close to 50 percent objective response. We believe that by using intravenous antineoplastons in combination with targeted medications we can substantially improve our success rate.
During our clinical trials, we accumulated data on 359 incurable brain tumors (gliomas). These are some of the most difficult malignancies to treat; they include glioblastoma and brainstem glioma. After treatment, 88 patients obtained objective responses. A complete response was identified in 57 percent (complete disappearance of the tumors) and partial response was achieved in 43 percent of patients (more than 50 percent reduction of tumor size). Survival in excess of five years was established in 39 percent of patients, and a number of patients have survived tumor free for more than ten years. The truth is that a number of our cancer patients accomplished cure of their disease in some of the most difficult types of malignancies in the entire oncology.
We don’t need to wait another forty years for a cancer cure. A cancer cure exists in America now, but it is available to only a small number of patients, and every patient requires individual permission from the FDA to be treated. The Promised Land is already visible, but it is up to the American people how soon it can be entered.
Last edited:
